Roche Holding AG (0QOK.IL)

220,00 +1,45 (+0,66%) In data: 02:31PM BST. Mercato aperto.

Roche Holding AG

Grenzacherstrasse 124
Basel 4058
Switzerland
41 61 688 11 11
https://www.roche.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 103.613

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Severin Schwan Ph.D.	Exec. Chairman	7,51M	N/D	1967
Dr. Thomas Schinecker	Chief Exec. Officer	3,87M	N/D	1975
Dr. Alan Hippe	Chief Financial & Information Officer	4,11M	N/D	1967
Ms. Cristina A. Wilbur	Chief People Officer	2,92M	N/D	1967
Dr. Johannes Carolus Clevers M.D., Ph.D.	Head of Roche Pharma Research & Early Devel.	82,5k	N/D	1957
Dr. Bruno Eschli	Head of Investor Relations	N/D	N/D	N/D
Ms. Claudia Bockstiegel	Gen. Counsel	N/D	N/D	1964
Ms. Pascale Schmidt	Chief Compliance Officer	N/D	N/D	1973
Ms. Barbara Schadler	Head of Group Communications	N/D	N/D	1962
Dr. Nicolas Dunant	Head of Group Media Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Roche Holding AG al 1 ottobre 2023 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.